Published online Sep 29, 2022. doi: 10.5495/wjcid.v12.i2.50
Peer-review started: June 18, 2022
First decision: July 14, 2022
Revised: August 2, 2022
Accepted: September 21, 2022
Article in press: September 21, 2022
Published online: September 29, 2022
During the peak of the coronavirus diseases 2019 (COVID-19) pandemic, cli
To study the influence of SARS-CoV-2 anti-nucleocapsid-IgG seropositivity on clinical course and diseases severity in hospitalized COVID-19 patients.
We conducted a retrospective study of adults admitted to a tertiary care com
After a thorough examination of patient data, it was found that admission rates to the Intensive Care Unit, as well as the usage of BiPAP, HFNC and VENT support, in conjunction with patient outcomes, were not significantly different across IgG-N status. However, the LOS variable when assessed by IgG-N status was found to be significant (t value = 2.16, P value = 0.0349). IgG-N negative patients had higher than average LOS in comparison to IgG-N positive patients (15.12 vs 9.35 d). Even when removing the extreme value (an LOS of 158 d), IgG-N negative patients still had slightly higher than average stays (10.66 vs 9.35 d) but the relationship was no longer significant. For patient outcome/death, only age (numerical) was a significant predictor (F value = 4.66, P value = 0.0352). No other variables for any of the outcomes were significant predictors of clinical course or disease severity.
Our study demonstrated that IgG-N seroconversion had no significant association with clinical outcomes in hospitalized COVID-19 patients.
Core Tip: We intended to study an immunologic marker to predict the need for advanced oxygen supplement system and clinical outcome in order to support our hospital crisis management system during the peak of the pandemic. Our study demonstrated that presence of anti-nucleocapsid-IgG (IgG-N) against severe acute respiratory syndrome coronavirus 2 infection had no impact on the clinical outcome or disease severity in hospitalized coronavirus disease 2019 (COVID-19) patients. We did not find a correlation of statistical significance to use IgG-N as a biomarker to predict clinical outcome in COVID-19 patients admitted to a community hospital in North Dakota.